Table 1.
Baseline characteristics
| Parameter | All (n = 639) | No cRBBB ≤ 30 days after HTX (n = 500) | cRBBB ≤ 30 days after HTX (n = 139) | Difference | 95% CI | P‐value |
|---|---|---|---|---|---|---|
| Recipient data | ||||||
| Age (years), mean ± SD | 52.1 ± 10.3 | 51.6 ± 10.5 | 53.8 ± 9.5 | 2.2 | 0.4–4.0 | 0.02* |
| Male sex, n (%) | 498 (77.9%) | 388 (77.6%) | 110 (79.1%) | 1.5% | −6.2%–9.2% | 0.70 |
| Body mass index (kg/m2), mean ± SD | 24.9 ± 4.0 | 24.9 ± 3.9 | 25.2 ± 4.3 | 0.3 | −0.5–1.1 | 0.45 |
| Arterial hypertension, n (%) | 350 (54.8%) | 269 (53.8%) | 81 (58.3%) | 4.5% | −4.8%–13.8% | 0.35 |
| Dyslipidaemia, n (%) | 406 (63.5%) | 323 (64.6%) | 83 (59.7%) | 4.9% | −4.3%–14.1% | 0.29 |
| Diabetes mellitus, n (%) | 215 (33.6%) | 169 (33.8%) | 46 (33.1%) | 0.7% | −8.2%–9.6% | 0.88 |
| COPD, n (%) | 155 (24.3%) | 109 (21.8%) | 46 (33.1%) | 11.3% | 2.7%–19.9% | 0.01* |
| Renal insufficiency a , n (%) | 368 (57.6%) | 287 (57.4%) | 81 (58.3%) | 0.9% | −8.4%–10.2% | 0.85 |
| eGFR (ml/min/1.73 m2), mean ± SD | 60.3 ± 21.7 | 60.7 ± 22.0 | 58.9 ± 20.5 | 1.8 | −2.1–5.7 | 0.37 |
| Previous open‐heart surgery | ||||||
| Overall open‐heart surgery, n (%) | 190 (29.7%) | 146 (29.2%) | 44 (31.7%) | 2.5% | −6.2%–11.2% | 0.58 |
| CABG surgery, n (%) | 78 (12.2%) | 59 (11.8%) | 19 (13.7%) | 1.9% | −4.5%–8.3% | 0.55 |
| Other surgery b , n (%) | 71 (11.1%) | 56 (11.2%) | 15 (10.8%) | 0.4% | −5.4%–6.2% | 0.89 |
| VAD surgery, n (%) | 55 (8.6%) | 40 (8.0%) | 15 (10.8%) | 2.8% | −2.9%–8.5% | 0.30 |
| Principal diagnosis for HTX | ||||||
| Ischaemic CMP, n (%) | 209 (32.7%) | 160 (32.0%) | 49 (35.2%) | 3.2% | −5.7%–12.1% | 0.47 |
| Non‐ischaemic CMP, n (%) | 339 (53.1%) | 269 (53.8%) | 70 (50.4%) | 3.4% | −6.0%–12.8% | 0.47 |
| Valvular heart disease, n (%) | 34 (5.3%) | 26 (5.2%) | 8 (5.8%) | 0.6% | −3.7%–4.9% | 0.80 |
| Cardiac amyloidosis, n (%) | 57 (8.9%) | 45 (9.0%) | 12 (8.6%) | 0.4% | −4.9%–5.7% | 0.89 |
| Donor data | ||||||
| Age (years), mean ± SD | 41.0 ± 13.4 | 40.2 ± 13.4 | 43.8 ± 13.2 | 3.6 | 1.1–6.1 | 0.01* |
| Male sex, n (%) | 278 (43.5%) | 221 (44.2%) | 57 (41.0%) | 3.2% | −6.1%–12.5% | 0.50 |
| Body mass index (kg/m2), mean ± SD | 24.8 ± 4.1 | 24.8 ± 4.1 | 24.8 ± 4.0 | 0.0 | −0.8–0.8 | 0.99 |
| Transplant sex mismatch | ||||||
| Mismatch, n (%) | 283 (44.3%) | 215 (43.0%) | 68 (48.9%) | 5.9% | −3.5%–15.3% | 0.21 |
| Donor (m) to recipient (f), n (%) | 31 (4.9%) | 24 (4.8%) | 7 (5.0%) | 0.2% | −3.9%–4.3% | 0.91 |
| Donor (f) to recipient (m), n (%) | 252 (39.4%) | 191 (38.2%) | 61 (43.9%) | 5.7% | −3.6%–15.0% | 0.23 |
| Preoperative data | ||||||
| RAP (mmHg), mean ± SD | 10.8 ± 4.1 | 10.5 ± 4.0 | 11.8 ± 4.0 | 1.3 | 0.5–2.1 | <0.01* |
| RVP (mmHg), mean ± SD | 14.5 ± 5.0 | 14.2 ± 4.9 | 15.7 ± 5.2 | 1.5 | 0.5–2.5 | <0.01* |
| PASP (mmHg), mean ± SD | 42.8 ± 12.4 | 41.9 ± 12.4 | 45.9 ± 11.9 | 4.0 | 1.7–6.3 | <0.01* |
| PADP (mmHg), mean ± SD | 21.9 ± 7.4 | 21.3 ± 7.3 | 23.9 ± 7.4 | 2.6 | 1.2–4.0 | <0.01* |
| PAPi (value), mean ± SD | 2.1 ± 0.9 | 2.1 ± 1.0 | 2.0 ± 0.8 | 0.1 | −0.1–0.3 | 0.16 |
| PVR (dyn·s·cm−5), mean ± SD | 207.9 ± 103.4 | 198.1 ± 97.2 | 243.2 ± 116.2 | 45.1 | 23.8–66.4 | <0.01* |
| Perioperative data | ||||||
| Ischaemic time (min), mean ± SD | 223.4 ± 68.4 | 220.2 ± 67.4 | 235.0 ± 70.7 | 14.8 | 1.6–28.0 | 0.03* |
| Biatrial HTX, n (%) | 164 (25.7%) | 131 (26.2%) | 33 (23.7%) | 2.5% | −5.5%–10.5% | 0.56 |
| Bicaval HTX, n (%) | 198 (31.0%) | 157 (31.4%) | 41 (29.5%) | 1.9% | −6.7%–10.5% | 0.67 |
| Total orthotopic HTX, n (%) | 277 (43.3%) | 212 (42.4%) | 65 (46.8%) | 4.4% | −5.0%–13.8% | 0.36 |
CABG, coronary artery bypass graft; CI, confidence interval; CMP, cardiomyopathy; COPD, chronic obstructive pulmonary disease; cRBBB, complete right bundle branch block; f, female; eGFR, estimated glomerular filtration rate; HTX, heart transplantation; m, male; n, number; PADP, pulmonary artery diastolic pressure; PAPi, pulmonary artery pulsatility index; PASP, pulmonary artery systolic pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RVP, right ventricular pressure; SD, standard deviation; VAD, ventricular assist device.
a
eGFR < 60 mL/min/1.73 m2.
b
Congenital, valvular or ventricular surgery.
*
Statistically significant at P < 0.05.